Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Abstract

OBJECTIVE To delineate the clinical characteristics of patients with coronavirus disease 2019 (covid-19) who died. DESIGN Retrospective case series. SETTING Tongji Hospital in Wuhan, China.PARTICIPANTS Among a cohort of 799 patients, 113 who died and 161 who recovered with a diagnosis of covid-19 were analysed. Data were collected until 28 February 2020. MAIN OUTCOME MEASURESClinical characteristics and laboratory findings were obtained from electronic medical records with data collection forms. RESULTSThe median age of deceased patients (68 years) was significantly older than recovered patients (51 years). Male sex was more predominant in deceased patients (83; 73%) than in recovered patients (88; 55%). Chronic hypertension and other cardiovascular comorbidities were more frequent among deceased patients (54 (48%) and 16 (14%)) than recovered patients (39 (24%) and 7 (4%)). Dyspnoea, chest tightness, and disorder of consciousness were more common in deceased patients (70 (62%), 55 (49%), and 25 (22%)) than in recovered patients (50 (31%), 48 (30%), and 1 (1%)). The median time from disease onset to death in deceased patients was 16 (interquartile range 12.0-20.0) days. Leukocytosis was present in 56 (50%) patients who died and 6 (4%) who recovered, and lymphopenia was present in 103 (91%) and 76 (47%) respectively. Concentrations of alanine aminotransferase, aspartate aminotransferase, creatinine, creatine kinase, lactate dehydrogenase, cardiac troponin I, N-terminal pro-brain natriuretic peptide, and D-dimer were markedly higher in deceased patients than in recovered patients. Common complications observed more frequently in deceased patients included acute respiratory distress syndrome (113; 100%), type I respiratory failure (18/35; 51%), sepsis (113; 100%), acute cardiac injury (72/94; 77%), heart failure (41/83; 49%), alkalosis (14/35; 40%), hyperkalaemia (42; 37%), acute kidney injury (28; 25%), and hypoxic encephalopathy (23; 20%). Patients with cardiovascular comorbidity were more likely to develop cardiac complications. Regardless of history of cardiovascular disease, acute cardiac injury and heart failure were more common in deceased patients. CONCLUSIONSevere acute respiratory syndrome coronavirus 2 infection can cause both pulmonary and systemic inflammation, leading to multi-organ dysfunction in patients at high risk. Acute respiratory distress syndrome and respiratory failure, sepsis, acute cardiac injury, and heart failure were the most common critical complications during exacerbation of covid-19.

Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study

“…In this study, only 10% of patients received corticosteroid treatment compared to 50%-79% as reported in patients from Wuhan [7,9]. Our analysis indicated that corticosteroid use was associated with delayed viral RNA clearance, in line with a recent report from Wuhan [18].…”

“…To date, several epidemiological studies have reported the clinical characteristics of COVID-19 [1][2][3][6][7][8][9]. Most of these studies with large sample size came from Wuhan, the center of the outbreak where sudden surge in demands for medical care has influenced timely treatment resulting in serious illness.…”

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System

“…Cerebrovascular diseases are among the comorbidities of patients with confirmed COVID-19 who develop severe respiratory complications [1]. For example, one study reported hypoxic/ischemic encephalopathy in~20% of 113 deceased patients with COVID-19 [2]. A recent study evaluated 214 patients diagnosed with COVID-19 from China and found that 36% had neurological manifestations, 46 including acute cerebrovascular disease and impaired consciousness [3]; a case 48 of acute hemorrhagic necrotizing enceph-49 alopathy has also been reported [4].…”

Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience

“…Some patients may quickly progress to severe or critical cases, with acute respiratory distress syndrome (ARDS), sepsis and multiple organ dysfunction, particular in patients with complicated underlying diseases (diabetes, cardiovascular disease, malignancy, etc.). 4,5 Therefore, personalized, collaborative and multidisciplinary management is of great significance to improve patients' outcomes. With the pandemic getting increasingly serious, Chinese solution of "centralizing COVID-19 patients and centralized inpatient treatment" provides certain reference for other countries to control the pandemic.…”